Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα ...

2 days ago · INDIANAPOLIS and BOSTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology …

$2
OFF

Eli Lilly To Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor …

2 weeks from now

1 day ago · NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop …

precisionmedicineonline.com

$2
OFF

Lilly Inks $2.5B Scorpion Buyout In Twist To Breast Cancer Tale

2 weeks from now

1 day ago · Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion …

fiercebiotech.com

$2
OFF

Lilly Catches Relay In PI3Ka Race Via Scorpion Acquisition

2 weeks from now

1 day ago · Eli Lilly is taking another shot at PI3Ka inhibition to bolster its breast cancer pipeline through a deal to acquire Scorpion. The deal, worth up to $2.5 billion including an undisclosed …

biocentury.com

$2
OFF

Eli Lilly To Buy Scorpion Therapeutics' Cancer Therapy For Up To $2.5 ...

2 weeks from now

1 day ago · Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 ...

cnbc.com

$2
OFF

Eli Lilly Snaps Up PI3Kα Inhibitor | Cancer Discovery News

2 weeks from now

2 days ago · Eli Lilly will acquire STX-478, a PI3Kα inhibitor for breast cancer and other solid tumors, from Scorpion Therapeutics in a deal that could be worth up to $2.5 billion for …

aacrjournals.org

$2
OFF

Eli Lilly To Acquire Scorpion For Up To $2.5B - MSN

2 weeks from now

Eli Lilly (NYSE:LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity focused on precision medicine. …

msn.com

$2
OFF

Eli Lilly Targets Scorpion Therapeutics To Expand Reach In Oncology

2 weeks from now

1 day ago · Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to …

pharmaceutical-technology.com

$8
OFF

Lilly Buys In Another PI3Kα Inhibitor | ApexOnco - Clinical Trials …

2 weeks from now

2 days ago · The co-founder of Loxo Oncology, sold to Lilly for $8bn six years ago, has just seen his subsequent oncology company, Scorpion Therapeutics, taken over by Lilly in deal focused …

oncologypipeline.com

$2
OFF

Lilly Circles $2.5B Scorpion Buy As Pre-JPM Rumour Mill Churns

2 weeks from now

5 days ago · Eli Lilly is said to be in advanced discussions to acquire cancer-focused biotech Scorpion Therapeutics for up to $2.5 billion, marking the second major potential acquisition …

firstwordpharma.com

FAQs about Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα ... Coupon?

Did Eli Lilly buy PI3Ka inhibitor stx-478?

(RTTNews) - Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor program STX-478 for up to $2.5 billion in cash. ...

Will Eli Lilly buy Scorpion Therapeutics?

Eli Lilly (NYSE: LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity focused on precision medicine. ...

How much will Lilly pay Scorpion shareholders?

Scorpion's lead drug asset, a mutant-selective PI3Kα inhibitor known as STX-478, is currently in Phase 1/2 testing for the treatment of breast cancer and other solid tumors. Under the deal, Lilly will pay Scorpion shareholders up to $2.5B in cash, including an upfront payment and potential milestone payments. ...

Does Scorpion own PI3Ka?

Additionally, as part of the transaction, Scorpion will spin out a new entity to hold its employees and non-PI3Ka pipeline assets. The new, independent company would be owned by Scorpion's current shareholders with Lilly holding a minority equity interest. ...

Is stx-478 a PI3Ka inhibitor?

STX-478 is a once-daily oral, mutant-selective PI3Ka inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. ...

Could stx-478 be the next generation of PI3Ka targeting agents?

STX-478 could represent the next generation of PI3Ka targeting agents by selectively targeting the pathway in cancerous but not healthy cells, thus overcoming a key limitation of currently available medicines that target the PI3Ka pathway. ...